No Cover Image

Journal article 536 views 51 downloads

The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer

Mari Jones Orcid Logo, Julia Lowin, Berni Sewell, Rachel Gemine, Sarah Rees Orcid Logo, Kirsty Lanyon Orcid Logo, Keir Lewis Orcid Logo

Value in Health, Volume: 26, Issue: 8, Pages: 1192 - 1200

Swansea University Authors: Mari Jones Orcid Logo, Julia Lowin, Berni Sewell, Rachel Gemine, Sarah Rees Orcid Logo, Kirsty Lanyon Orcid Logo, Keir Lewis Orcid Logo

  • 63282.pdf

    PDF | Version of Record

    c. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

    Download (787.42KB)

Check full text

DOI (Published version): 10.1016/j.jval.2023.03.2429

Abstract

Stopping smoking has proven benefits in nearly all illnesses but the impact and health economic benefits of stopping smoking following a diagnosis of lung cancer are less well defined. We assessed the cost-effectiveness of smoking cessation (SC) services for newly diagnosed lung cancer patients agai...

Full description

Published in: Value in Health
ISSN: 1098-3015
Published: Elsevier BV 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63282
first_indexed 2023-05-05T04:54:40Z
last_indexed 2024-11-15T18:01:18Z
id cronfa63282
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2024-03-05T09:30:36.4371313</datestamp><bib-version>v2</bib-version><id>63282</id><entry>2023-04-28</entry><title>The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non&#x2013;Small Cell Lung Cancer</title><swanseaauthors><author><sid>8e326860810f5f960b088db10ef58906</sid><ORCID>0000-0001-9661-4899</ORCID><firstname>Mari</firstname><surname>Jones</surname><name>Mari Jones</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>a9897f4e67e285093fefafcb1c954364</sid><firstname>Julia</firstname><surname>Lowin</surname><name>Julia Lowin</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>f6a4af2cfa4275d2a8ebba292fa14421</sid><firstname>Berni</firstname><surname>Sewell</surname><name>Berni Sewell</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>f6d0b85d0d231588029524ee2e442e56</sid><firstname>Rachel</firstname><surname>Gemine</surname><name>Rachel Gemine</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>86073be88970f36d7ffa0a1f0768be2b</sid><ORCID>0000-0002-1939-0120</ORCID><firstname>Sarah</firstname><surname>Rees</surname><name>Sarah Rees</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>a3f45c952158fb8d56dc7dbff5a4cf2d</sid><ORCID>0000-0002-4227-6852</ORCID><firstname>Kirsty</firstname><surname>Lanyon</surname><name>Kirsty Lanyon</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>bc53c343c975d6e0ad88c1d8b9ddd70c</sid><ORCID>0000-0002-8248-6774</ORCID><firstname>Keir</firstname><surname>Lewis</surname><name>Keir Lewis</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-04-28</date><deptcode>HSOC</deptcode><abstract>Stopping smoking has proven benefits in nearly all illnesses but the impact and health economic benefits of stopping smoking following a diagnosis of lung cancer are less well defined. We assessed the cost-effectiveness of smoking cessation (SC) services for newly diagnosed lung cancer patients against current usual care, where patients are unlikely to receive SC service referral. A health economic model was constructed in Excel. The modelled population comprised patients with a new diagnosis of non-small-cell lung cancer (NSCLC). Data from the LungCast dataset (Clinical Trials Identifier NCT01192256) were used to estimate model inputs. A structured search of published literature identified inputs not represented in LungCast, including healthcare resource use and costs. Costs were estimated from a 2020/21 UK NHS and Personal Social Services (PSS) perspective. The model estimated the incremental quality-adjusted adjusted life year (QALY) gained in newly diagnosed NSCLC patients receiving targeted SC intervention compared to those receiving no intervention. Extensive one-way sensitivity analyses (SA) explored input and dataset uncertainty.Results: In the five-year base-case, the model estimated an incremental cost of &#xA3;14,904 per QALY gained through SC intervention. Sensitivity analysis estimated an outcome range of between &#xA3;9,935 and &#xA3;32,246 per QALY gained. The model was most sensitive to the estimates of relative quit rates and expected healthcare resource use.</abstract><type>Journal Article</type><journal>Value in Health</journal><volume>26</volume><journalNumber>8</journalNumber><paginationStart>1192</paginationStart><paginationEnd>1200</paginationEnd><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1098-3015</issnPrint><issnElectronic/><keywords>cost, economic model, non&#x2013;small cell lung cancer, quality-adjusted life-year, smoking cessation</keywords><publishedDay>1</publishedDay><publishedMonth>8</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-08-01</publishedDate><doi>10.1016/j.jval.2023.03.2429</doi><url>http://dx.doi.org/10.1016/j.jval.2023.03.2429</url><notes/><college>COLLEGE NANME</college><department>Health and Social Care School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HSOC</DepartmentCode><institution>Swansea University</institution><apcterm>SU Library paid the OA fee (TA Institutional Deal)</apcterm><funders/><projectreference/><lastEdited>2024-03-05T09:30:36.4371313</lastEdited><Created>2023-04-28T15:56:33.8863952</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">School of Health and Social Care - Public Health</level></path><authors><author><firstname>Mari</firstname><surname>Jones</surname><orcid>0000-0001-9661-4899</orcid><order>1</order></author><author><firstname>Julia</firstname><surname>Lowin</surname><order>2</order></author><author><firstname>Berni</firstname><surname>Sewell</surname><order>3</order></author><author><firstname>Rachel</firstname><surname>Gemine</surname><order>4</order></author><author><firstname>Sarah</firstname><surname>Rees</surname><orcid>0000-0002-1939-0120</orcid><order>5</order></author><author><firstname>Kirsty</firstname><surname>Lanyon</surname><orcid>0000-0002-4227-6852</orcid><order>6</order></author><author><firstname>Keir</firstname><surname>Lewis</surname><orcid>0000-0002-8248-6774</orcid><order>7</order></author></authors><documents><document><filename>63282__27560__0188e07a58fe4b43a9b71ab6a6b0fb24.pdf</filename><originalFilename>63282.pdf</originalFilename><uploaded>2023-05-22T14:12:43.0838966</uploaded><type>Output</type><contentLength>806317</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>c. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2024-03-05T09:30:36.4371313 v2 63282 2023-04-28 The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer 8e326860810f5f960b088db10ef58906 0000-0001-9661-4899 Mari Jones Mari Jones true false a9897f4e67e285093fefafcb1c954364 Julia Lowin Julia Lowin true false f6a4af2cfa4275d2a8ebba292fa14421 Berni Sewell Berni Sewell true false f6d0b85d0d231588029524ee2e442e56 Rachel Gemine Rachel Gemine true false 86073be88970f36d7ffa0a1f0768be2b 0000-0002-1939-0120 Sarah Rees Sarah Rees true false a3f45c952158fb8d56dc7dbff5a4cf2d 0000-0002-4227-6852 Kirsty Lanyon Kirsty Lanyon true false bc53c343c975d6e0ad88c1d8b9ddd70c 0000-0002-8248-6774 Keir Lewis Keir Lewis true false 2023-04-28 HSOC Stopping smoking has proven benefits in nearly all illnesses but the impact and health economic benefits of stopping smoking following a diagnosis of lung cancer are less well defined. We assessed the cost-effectiveness of smoking cessation (SC) services for newly diagnosed lung cancer patients against current usual care, where patients are unlikely to receive SC service referral. A health economic model was constructed in Excel. The modelled population comprised patients with a new diagnosis of non-small-cell lung cancer (NSCLC). Data from the LungCast dataset (Clinical Trials Identifier NCT01192256) were used to estimate model inputs. A structured search of published literature identified inputs not represented in LungCast, including healthcare resource use and costs. Costs were estimated from a 2020/21 UK NHS and Personal Social Services (PSS) perspective. The model estimated the incremental quality-adjusted adjusted life year (QALY) gained in newly diagnosed NSCLC patients receiving targeted SC intervention compared to those receiving no intervention. Extensive one-way sensitivity analyses (SA) explored input and dataset uncertainty.Results: In the five-year base-case, the model estimated an incremental cost of £14,904 per QALY gained through SC intervention. Sensitivity analysis estimated an outcome range of between £9,935 and £32,246 per QALY gained. The model was most sensitive to the estimates of relative quit rates and expected healthcare resource use. Journal Article Value in Health 26 8 1192 1200 Elsevier BV 1098-3015 cost, economic model, non–small cell lung cancer, quality-adjusted life-year, smoking cessation 1 8 2023 2023-08-01 10.1016/j.jval.2023.03.2429 http://dx.doi.org/10.1016/j.jval.2023.03.2429 COLLEGE NANME Health and Social Care School COLLEGE CODE HSOC Swansea University SU Library paid the OA fee (TA Institutional Deal) 2024-03-05T09:30:36.4371313 2023-04-28T15:56:33.8863952 Faculty of Medicine, Health and Life Sciences School of Health and Social Care - Public Health Mari Jones 0000-0001-9661-4899 1 Julia Lowin 2 Berni Sewell 3 Rachel Gemine 4 Sarah Rees 0000-0002-1939-0120 5 Kirsty Lanyon 0000-0002-4227-6852 6 Keir Lewis 0000-0002-8248-6774 7 63282__27560__0188e07a58fe4b43a9b71ab6a6b0fb24.pdf 63282.pdf 2023-05-22T14:12:43.0838966 Output 806317 application/pdf Version of Record true c. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) true eng http://creativecommons.org/licenses/by/4.0/
title The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
spellingShingle The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
Mari Jones
Julia Lowin
Berni Sewell
Rachel Gemine
Sarah Rees
Kirsty Lanyon
Keir Lewis
title_short The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
title_full The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
title_fullStr The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
title_full_unstemmed The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
title_sort The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
author_id_str_mv 8e326860810f5f960b088db10ef58906
a9897f4e67e285093fefafcb1c954364
f6a4af2cfa4275d2a8ebba292fa14421
f6d0b85d0d231588029524ee2e442e56
86073be88970f36d7ffa0a1f0768be2b
a3f45c952158fb8d56dc7dbff5a4cf2d
bc53c343c975d6e0ad88c1d8b9ddd70c
author_id_fullname_str_mv 8e326860810f5f960b088db10ef58906_***_Mari Jones
a9897f4e67e285093fefafcb1c954364_***_Julia Lowin
f6a4af2cfa4275d2a8ebba292fa14421_***_Berni Sewell
f6d0b85d0d231588029524ee2e442e56_***_Rachel Gemine
86073be88970f36d7ffa0a1f0768be2b_***_Sarah Rees
a3f45c952158fb8d56dc7dbff5a4cf2d_***_Kirsty Lanyon
bc53c343c975d6e0ad88c1d8b9ddd70c_***_Keir Lewis
author Mari Jones
Julia Lowin
Berni Sewell
Rachel Gemine
Sarah Rees
Kirsty Lanyon
Keir Lewis
author2 Mari Jones
Julia Lowin
Berni Sewell
Rachel Gemine
Sarah Rees
Kirsty Lanyon
Keir Lewis
format Journal article
container_title Value in Health
container_volume 26
container_issue 8
container_start_page 1192
publishDate 2023
institution Swansea University
issn 1098-3015
doi_str_mv 10.1016/j.jval.2023.03.2429
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str School of Health and Social Care - Public Health{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}School of Health and Social Care - Public Health
url http://dx.doi.org/10.1016/j.jval.2023.03.2429
document_store_str 1
active_str 0
description Stopping smoking has proven benefits in nearly all illnesses but the impact and health economic benefits of stopping smoking following a diagnosis of lung cancer are less well defined. We assessed the cost-effectiveness of smoking cessation (SC) services for newly diagnosed lung cancer patients against current usual care, where patients are unlikely to receive SC service referral. A health economic model was constructed in Excel. The modelled population comprised patients with a new diagnosis of non-small-cell lung cancer (NSCLC). Data from the LungCast dataset (Clinical Trials Identifier NCT01192256) were used to estimate model inputs. A structured search of published literature identified inputs not represented in LungCast, including healthcare resource use and costs. Costs were estimated from a 2020/21 UK NHS and Personal Social Services (PSS) perspective. The model estimated the incremental quality-adjusted adjusted life year (QALY) gained in newly diagnosed NSCLC patients receiving targeted SC intervention compared to those receiving no intervention. Extensive one-way sensitivity analyses (SA) explored input and dataset uncertainty.Results: In the five-year base-case, the model estimated an incremental cost of £14,904 per QALY gained through SC intervention. Sensitivity analysis estimated an outcome range of between £9,935 and £32,246 per QALY gained. The model was most sensitive to the estimates of relative quit rates and expected healthcare resource use.
published_date 2023-08-01T14:24:30Z
_version_ 1821325205930246144
score 11.048042

Similar Items